2023年欧洲肿瘤内科学会（ESMO）年会将于当地时间10月20-24日在西班牙马德里召开。正大天晴三大创新药安罗替尼、派安普利单抗、贝莫苏拜单抗以及氟维司群共有21项研究入选壁报展示，涉及非小细胞肺癌、小细胞肺癌、软组织肉瘤、骨肉瘤、食管癌、肝细胞癌、乳腺癌、宫颈癌、鼻咽癌、脑胶质瘤等肿瘤领域。

肺癌

1. 安罗替尼联合PD-1/PD-L1抑制剂一线或二线治疗晚期非小细胞肺癌的疗效和安全性：一项真实世界研究的结果更新

1487P-Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer: Updated results

汇报人：河南省肿瘤医院 王启鸣

2. 贝莫苏拜单抗联合化疗诱导治疗后手术或放疗在局限期小细胞肺癌患者中的疗效和安全性：一项II期研究

1991P-Safety and Effectiveness of Surgery or Radiotherapy after PD-L1 Inhibitor (TQB-2450) and Chemotherapy Induction Therapy in Patients with Limited-stage Small-cell Lung Cancer: a Phase 2 Trial

汇报人：上海市肺科医院 孙凤环

3. 安罗替尼联合信迪利单抗及化疗二线及以上治疗广泛期小细胞肺癌

1997P-A Study of Sintilimab Combined with Anlotinib and chemotherapy as Second-Line or Later Therapy in Extensive-Disease Small Cell Lung Cancer

汇报人：山东省肿瘤医院 王哲海

4. 安罗替尼联合化疗一线治疗广泛期小细胞肺癌的真实世界研究

2005P-Anlotinib combined with chemotherapy in the treatment of first-line extensive- stage small cell lung cancer（ES-SCLC）: A real-world study

汇报人：河南省肿瘤医院 高方方

肉瘤

5. 安罗替尼联合聚乙二醇化脂质体多柔比星新辅助治疗局晚期软组织肉瘤的单臂、II期研究

1950P-A single-arm, phase II clinical trial of Neoadjuvant pegylated liposomal doxorubicin plus anlotinib in locally advanced soft tissue sarcoma

汇报人：复旦大学附属肿瘤医院 陈勇

6. 安罗替尼联合艾立布林及卡瑞利珠单抗治疗晚期或转移性腹膜后脂肪肉瘤或平滑肌肉瘤的疗效和安全性：一项单中心回顾性队列研究

1943P-Efficacy and safety of eribulin plus anlotinib and camrelizumab in advanced or metastatic retroperitoneal liposarcoma (RLPS) or leiomyosarcoma (RLMS): a single-center retrospective cohort study

汇报人：北京大学肿瘤医院 吴剑挥

7. 安罗替尼联合化疗治疗IIB期肢体经典型骨肉瘤的单臂、多中心研究

1967P-A single-arm multicenter trial of the combination of anlotinib with chemotherapy in patients with Stage IIB classic osteosarcoma of the extremity

汇报人：四川大学华西医院 唐凡

消化道肿瘤

8. ALTER-G-001：安罗替尼联合化疗一线治疗伴不可切除肝转移消化道肿瘤的多队列、多中心、II期研究初步结果

1628P-Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)

汇报人：上海交通大学医学院附属瑞金医院 吴珺玮

9. 安罗替尼联合贝莫苏拜单抗一线治疗晚期食管鳞癌：一项单臂、多中心、开放性II期研究的结果更新

1531P-Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): a single-arm, multicenter, open-label phase Ⅱ clinical trial

汇报人：安阳市肿瘤医院 洪永贵

10. 安罗替尼联合PD-1抑制剂及紫杉醇和卡铂一线治疗晚期食管癌的II期研究结果更新

1542P-Updated results of a phase Ⅱ clinical trial: paclitaxel and carboplatin plus PD-1 blockades combined with anlotinib as first-line treatment for advanced esophageal cancer

汇报人：陆军军医大学第三附属医院 许明芳

11. 安罗替尼联合放疗及替雷利珠单抗一线治疗肝细胞癌的单臂、II期研究

954P-Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: a single arm, phase Ⅱ clinical trial

汇报人：西南医科大学附属医院 巫桂舒

12. 安罗替尼联合贝莫苏拜单抗及HAIC辅助治疗肝切除术后伴高复发风险肝细胞癌的单中心、非随机、开放性临床研究

951P-HAIC combined with anlotinib and TQB2450 as adjuvant therapy for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after hepatectomy: a single-centre, non-randomised, open clinical study

汇报人：复旦大学附属肿瘤医院 张倜

妇科肿瘤

13. ALTN-AK105-II-06：派安普利单抗联合安罗替尼及减量化疗一线治疗持续性、复发性或转移性宫颈癌的单臂II期研究

763P-Penpulimab + anlotinib plus chemo-less therapy in first-line treatment for persistent, recurrent, or metastatic cervical cancer: a single-arm, phase Ⅱ study (ALTN-AK105-II-06)

汇报人：福建省肿瘤医院 徐沁

乳腺癌

14. 安罗替尼联合伊立替康二线及以上治疗 HER2 阴性晚期乳腺癌的前瞻性、单臂、单中心、探索性临床研究

450P-A prospective, single-arm, single-center, exploratory clinical study of anlotinib combined with irinotecan in second-line and above treatment of HER-2-negative advanced breast cancer

汇报人：江南大学附属医院 张颖

15. 安罗替尼联合紫杉类药物和洛铂新辅助治疗三阴性乳腺癌的II期研究：来自neoALTAL研究的疗效、安全性和生物标志物分析

246P-Phase 2 study of anlotinib combined with taxanes and lobaplatin in the neoadjuvant treatment of triple-negative breast cancer: efficacy, safety and biomarker analysis from the neoALTAL trial

汇报人：陆军军医大学第一附属医院 齐晓伟

16. 安罗替尼联合信迪利单抗及节拍化疗治疗晚期三阴性乳腺癌的疗效和安全性（SPACE）：一项单臂、多中心II期研究的初步结果

444P-Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple negative breast cancer (SPACE): preliminary results of a single-arm, multicenter phase II trial

汇报人：山东省肿瘤医院 李慧慧

17. 安罗替尼联合氟维司群治疗既往接受过芳香化酶抑制剂治疗的转移性乳腺癌的II期研究

452P-A Phase II Trial of Anlotinib and Fulvestrant in Patients with Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor

汇报人：浙江省肿瘤医院 王晓稼

18. 氟维司群联合化疗新辅助治疗HR阳性/HER2阴性局晚期乳腺癌的II期研究

361P-A phase 2 study of fulvestrant combined with chemotherapy in the neoadjuvant treatment of HR+/HER2- locally advanced breast cancer

汇报人：重庆大学附属肿瘤医院 吴静

头颈部肿瘤

19. 安罗替尼联合特瑞普利单抗治疗经治复发性或转移性鼻咽癌：一项单臂、II期TORAL研究的期中分析

912P-Toripalimab in combination with anlotinib in previously treated recurrent or metastatic nasopharyngeal carcinoma: the interim analysis of the single-arm, phase II TORAL study

汇报人：中山大学肿瘤防治中心 蔡清清

20. 基于MRI影像组学预测复发性恶性胶质瘤患者对安罗替尼联合替莫唑胺治疗的反应研究

515P-A MRI-based Radiomics Model for Predicting the Response to Anlotinib Combined with Temozolomide in Recurrent Malignant Glioma Patients

汇报人：江苏省人民医院 周树

肾上腺皮质癌

21. 安罗替尼联合替雷利珠单抗治疗转移性肾上腺皮质癌的临床结局：一项单臂、单中心研究结果

727P-Clinical outcome of Anlotinib(A) and Tislelizumab(T) in metastatic adrenocortical carcinoma(mACC): a one-arm single-center experience

汇报人：上海交通大学医学院附属瑞金医院 黎皓